For example, palovarotene, a retinoic acid receptor gamma (RAR-γ) agonist developed for use in emphysema, was found to be efficacious in an animal model of fibrodysplasia ossificans progressiva (FOP), and is now in phase 3 clinical trials (15). Here, RARG is linked to fibrodysplasia ossificans progressiva.